TP53 and liver cancer: Therefore, the development of JMJD2D inhibitors that can downregulate JMJD2D expression or block the interaction between JMJD2D and p53 may represent a novel strategy to restore the transcriptional activity of wild-type p53 for liver cancer treatment.